Vaccinex, Inc. · OTC:VCNX
Vaccinex — Investor Presentation (March 2019)
32 slides from Vaccinex's investor presentation, Mar 18, 2019
Slide 1: Science in the Service of Medicine
Exhibit 99.1 Science in the Service of Medicine Unique Targets. Novel Mechanisms. New Medicines. VX15 (pepinemab) Antibody Treatment for Cancer and Huntington’s Disease 1Exhibit 99.1 Science in the Service of Medicine Unique Targets. Novel Mechanisms. New Medicines. VX15 (pepinemab) Antibody Treatme
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Words such as “m
Slide 3: Investment Summary
Investment Summary Novel mechanistic Lead program, VX15 (pepinemab), is a humanized monoclonal antibody that binds to and blocks a unique target, Semaphorin 4D (SEMA4D) approach • Huntington’s Disease – fully enrolled ongoing randomized, placebo-controlled, potentially pivotal trial • Encouraging ea
Slide 4: Vaccinex Product Pipeline
Vaccinex Product Pipeline Research/Preclinical Phase 1 Phase 2 Phase 3 SEMA4D Antibody Platform VX15 (pepinemab) Huntington’s Disease (Orphan Disease and Fast Track Designation) CLASSICAL – Lung VX15 (pepinemab) Non-Small Cell Lung Cancer (with Merck KGaA) (with BMS and UCLA) VX15 (pepinemab) Melano
Slide 5: Introduction to Semaphorin 4D (SEMA4D)
Introduction to Semaphorin 4D (SEMA4D) SEMA4D signals through PLXNB1 and PLXNB2 receptors SEMA4D to regulate the cell cytoskeleton Crosslinking and signaling PLXNB1/ PLXNB2 VX15 (pepinemab) antibody binds to SEMA4D and blocks its signaling activity R-Ras, RhoA and ROCK-kinase Cytoskeletal reorganiza
Slide 6: VX15 (pepinemab) Anti-SEMA4D Antibody for Cancer
VX15 (pepinemab) Anti-SEMA4D Antibody for CancerVX15 (pepinemab) Anti-SEMA4D Antibody for Cancer
Slide 7: SEMA4D Expression is Concentrated at Invasive Margin of Tumor
SEMA4D Expression is Concentrated at Invasive Margin of Tumor Colorectal (Colon26) Mammary carcinoma (Tubo.A5) SEMA4D Pseudo color SEMA4D at the Antibodies against invasive margin of the SEMA4D neutralize tumor forms a barrier this barrier and “open that restricts the the gates” of the tumor infiltr
Slide 8: SEMA4D Controls Infiltration of Antigen Presenting Dendritic Cells into Tumor
SEMA4D Controls Infiltration of Antigen Presenting Dendritic Cells into Tumor Antigen Presenting Cells (APC) • Dendritic cells (DC) express PLXNB1 receptor for SEMA4D. Control • Binding of SEMA4D immobilizes DC and restricts penetration into tumor. • Antibody blockade of SEMA4D enhances CD11c F4/80
Slide 9: Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor
Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor T cell exclusion in Colon26 tumor Stroma Tumor Stroma Tumor Control group Anti-SEMA4D antibody CD8+ T cells (red) do not penetrate the tumor. Most CD8+ CD8+ T cells infiltrate the interior of the tumor cells are within the stroma and vessels
Slide 10: Anti-SEMA4D treatment shifts cytokines and chemokines in tumor microenvironment
Anti-SEMA4D treatment shifts the balance of cytokines and chemokines in the tumor microenvironment CCL2/ 10 March 2019 I Immunosuppressive Factors Tumoricidal FactorsAnti-SEMA4D treatment shifts the balance of cytokines and chemokines in the tumor microenvironment CCL2/ 10 March 2019 I Immunosuppres
Slide 11: Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors
Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors Anti-CTLA-4 Anti-LAG3 Combination with anti-SEMA4D Head & Neck Cancer Colorectal Cancer Colorectal Cancer Colon26 Control Control αSEMA4D αCTLA-4 αSEMA4D αSEMA4D + αLAG3 αCTLA-4 αLAG3+αSEMA4D 11 March 2019 I Anti-SEMA4D Antibody
Slide 12: T cell infiltration into tumor bed
T cell infiltration into tumor bed Neoadjuvant therapy: Colorectal cancer metastasis to liver No treatment Pepinemab Pepinemab + Ipilimumab T cells penetrate into the tumor bed and. . T cells are trapped at margin and are Tumor content is reduced and appears to The tumor bed consists mainly of strom
Slide 13: Phase 1b/2 Combination Trial with Avelumab in NSCLC
Phase 1b/2 Combination Trial with Avelumab in NSCLC VX15/2503 (pepinemab) in combination with avelumab (Anti-PD-L1) DOSE ESCALATION PHASE EXPANSION PHASE NSCLC To determine the recommended Phase 2 Patients will be stratified but unselected for immunotherapy naïve dose of VX15 (pepinemab) PD-L1; pre-
Slide 14: CLASSICAL-Lung: Pepinemab+Avelumab
T :T Ratio effector regulatory CLASSICAL-Lung: Pepinemab+Avelumab Pre-treatment • Pre-treatment tissue shows infiltrating malignant cells • Post-treatment biopsy demonstrates reactive alveolar Post-treatment parenchyma and inflammation. No evidence of tumor. Post-treatment 14 + + March 2019 I CD8 T
Slide 15: Combination Melanoma Trial with Nivolumab and with Ipilimumab
Combination Melanoma Trial with Nivolumab and with Ipilimumab VX15/2503 (pepine mab) combination with nivolumab (Anti-PD-1) or ipilimumab (Anti-CTLA-4) VX15/2503 (pepinemab) DOSE ESCALATION PHASE + nivolumab VX15 (pepinemab) dose will be escalated from 10 to 20 mg/kg, Q4W, with nivolumab EXPANSION P
Slide 16: VX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's Disease
VX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's DiseaseVX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's Disease
Slide 17: Huntington's Disease (HD)
Huntington’s Disease (HD) HD is an autosomal dominant neurodegenerative disease caused by mutation in a single gene • Neuronal degeneration and severe atrophy is observed in multiple brain regions • Symptoms usually appear between the ages of 30 to 50 Estimated patient population ~30,000 manifest di
Slide 18: Astrocytes reach out to touch and interact with other brain cells
Astrocytes reach out to touch and interact with other brain cells Astrocyte “arms” provide essential functional support to neurons. • Fully cover capillaries and facilitate glucose uptake from circulation • Cradle synapses and recycle glutamate • Positioned to couple energy metabolism with neuronal
Slide 19: Astrocytes Undergo Inflammatory Transformation that Aggravates Brain Damage in HD
Astrocytes Undergo Inflammatory Transformation that Aggravates Brain Damage in HD • CNS damage triggers a dramatic change in astrocyte morphology and function • Shift from direct contact with other cells to secretion of inflammatory mediators • this is beneficial in the context of acute focal injury
Slide 20: Astrocytes Undergo Inflammatory Transformation that Aggravates Brain Damage in HD
Astrocytes Undergo Inflammatory Transformation that Aggravates Brain Damage in HD • How do astrocytes recognize and respond to damage? • Astrocytes express high levels of receptors for SEMA4D • SEMA4D is upregulated at site of injury • SEMA4D triggers depolymerization of F-actin associated with tran
Slide 21: SEMA4D Inhibits Cell Migration and Process Extension
SEMA4D Inhibits Cell Migration and Process Extension A B F-actin Normal Control rSEMA4D Untreated rSEMA4D C PlexinB1 DAPI PHALLOIDIN DAPI PHALLOIDIN DAPI 21 March 2019 I Mean phalloidin area/cellSEMA4D Inhibits Cell Migration and Process Extension A B F-actin Normal Control rSEMA4D Untreated rSEMA4D
Slide 22: Clinical Trial: FDG-PET Treatment Effect - Mean Change Over 6 Months
Clinical Trial: FDG-PET Treatment Effect - Mean Change Over 6 Months FDG PET V(7-0)-P(7-0) FDG PET V(7-0)-P(7-0) A B % Change VX15 vs Placebo: REGION AVEs Difference in LS Means: Region AVEs CAUDAL MIDDLE FRONTAL CAUDAL MIDDLE FRONTAL PARSORBITALIS POSTCENTRAL PRECENTRAL PRECENTRAL ROSTRAL MIDDLE FR
Slide 23: SIGNAL Cohort A Data Highlights
SIGNAL Cohort A Data Highlights VX15 (pepinemab) treatment significantly increases metabolic activity as detected by FDG-PET: • Previous studies in Alzheimer’s Disease concluded that glucose metabolism is a sensitive measure of change in cognition and functional ability and has value in predicting f
Slide 24: Huntington's Disease Clinical Trial Design: Cohort B
Huntington’s Disease Clinical Trial Design: Cohort B Double- blind Database lock and 179 early manifest subjects Cohort B treatment with analysis for 1 month randomized 1:1 Drug:Placebo VX15 Group 1 safety Cohort B (pepinemab) follow-up 18 months 2020 Double- blind Database lock and Cohort B 86 late
Slide 25: Antibody Selection to Multi-Pass Membrane Receptors
Antibody Selection to Multi-Pass Membrane ReceptorsAntibody Selection to Multi-Pass Membrane Receptors
Slide 26: ActivMAb Viral envelope expression technology
® ActivMAb Viral envelope expression technology to display multi- pass membrane receptors so as to enable antibody selection against this important class of pharmaceutical targets® ActivMAb Viral envelope expression technology to display multi- pass membrane receptors so as to enable antibody select
Slide 27: Research Collaboration with Surface Oncology
Research Collaboration with • Announced January 2018 • Utilizes Vaccinex’s ActivMAb platform to discover and select monoclonal antibodies to two undisclosed membrane targets • Surface Oncology has the option to obtain exclusive worldwide rights to antibodies discovered during the research program •
Slide 28: Robust Patent Estate
Robust Patent Estate VX15 (pepinemab) US Patents and Patent Applications US No. 8,496,938 issued 7/30/13) Key Composition of Matter Claims Expected Exclusivity to 2030 (before patent term extension) US No. 9,243,9068 issued 1/26/16 Key Additional Method of Use US No. 9,249,227 issued 2/2/16 Claims f
Slide 29: Anticipated Milestones
Anticipated Milestones Event Timing Antibody Platform: Expected delivery of selected antibodies to Surface Oncology Q4 2018 Publish SIGNAL Cohort A Data in Huntington’s Disease H2 2019 ASCO 2019, Anticipated Initial Report of Open Label combination study of VX15 June 2019 (pepinemab) with avelumab i
Slide 30: Vaccinex Corporation
Vaccinex Corporation Clinical-stage immunotherapy company focused on the discovery and development of antibody therapies for neurodegenerative diseases and cancer VCNX (NASDAQ) Recent close $5.00 (2/8/2019) Shares outstanding 11.5M Market cap $57.5M Headquarters Rochester, NY Employees 44 (34 in R&D
Slide 31: Executive Management Team
Executive Management Team Maurice Zauderer, Ph.D. Formerly Professor at University of Founder, President & Chief Executive Officer Rochester and at Columbia University. Scott E. Royer, CFA, MBA Formerly CFO, Medical Films Division Chief Financial Officer of Carestream Health. John E. Leonard, Ph.D.
Slide 32: Vaccinex Board of Directors
Vaccinex Board of Directors Chairman, President and CEO of Friedberg Mercantile Group, a Toronto-based commodities and Albert D. Friedberg investment management firm he founded in 1971. He served as Chairman of the Toronto Futures Exchange from March 1985 to June 1988. Alejandro M. Berlin, M.D., MSc